GRI Bio Inc (GRI)

Currency in USD
1.410
-0.060(-4.08%)
Closed·
1.4100.000(0.00%)
·
Trading near 52-week Low
GRI is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.3901.490
52 wk Range
1.39080.360
Key Statistics
Prev. Close
1.47
Open
1.48
Day's Range
1.39-1.49
52 wk Range
1.39-80.36
Volume
27.64K
Average Volume (3m)
62.96K
1-Year Change
-97.5436%
Book Value / Share
7.3
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GRI Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
21.000
Upside
+1,389.36%
Members' Sentiments
Bearish
Bullish
ProTips
2 analysts have revised their earnings upwards for the upcoming period

GRI Bio Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 21.000
(+1,389.36% Upside)

Earnings

Latest Release
May 14, 2026
EPS / Forecast
-1.61 / -0.96
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

GRI Income Statement

Compare GRI to Peers and Sector

Metrics to compare
GRI
Peers
Sector
Relationship
P/E Ratio
−0.2x−2.0x−0.3x
PEG Ratio
0.00−0.030.00
Price/Book
0.2x2.4x2.6x
Price / LTM Sales
-89.2x2.9x
Upside (Analyst Target)
-356.8%56.7%
Fair Value Upside
Unlock18.8%10.2%Unlock

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
36.01K2.03%52.94K
Other Institutional Investors
13.58K0.77%19.97K
Public Companies & Retail Investors
1.72M97.20%2.53M
Total
1.77M100.00%2.6M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Vanguard Capital Management, LLC1.21%21,36831
Vanguard Index Funds - Vanguard Extended Market ETF1.21%21,36831

People Also Watch

0.349
VCIG
-10.41%
19.46
RLAY
+5.93%
1.670
MOBX
-7.73%
2.4500
UTSI
+5.60%

FAQ

What Is the GRI Bio (GRI) Stock Price Today?

The GRI Bio stock price today is 1.410 USD.

What Stock Exchange Does GRI Bio Trade On?

GRI Bio is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for GRI Bio?

The stock symbol for GRI Bio is "GRI."

What Is the GRI Bio Market Cap?

As of today, GRI Bio market cap is 2.530M USD.

What Is GRI Bio's Earnings Per Share (TTM)?

The GRI Bio EPS (TTM) is -27.019.

When Is the Next GRI Bio Earnings Date?

GRI Bio will release its next earnings report on Aug 19, 2026.

From a Technical Analysis Perspective, Is GRI a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has GRI Bio Stock Split?

GRI Bio has split 5 times.

How Many Employees Does GRI Bio Have?

GRI Bio has 4 employees.

What is the current trading status of GRI Bio (GRI)?

As of Jul 30, 2026, GRI Bio (GRI) is trading at a price of 1.410 USD, with a previous close of 1.470 USD. The stock has fluctuated within a day range of 1.390 USD to 1.490 USD, while its 52-week range spans from 1.390 USD to 80.360 USD.

What Is GRI Bio (GRI) Price Target According to Analysts?

The average 12-month price target for GRI Bio is 21.000 USD, with a high estimate of 32 USD and a low estimate of 10 USD. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +1,389.36% Upside potential.

What Is the GRI Premarket Price?

GRI's last pre-market stock price is 1.400 USD. The pre-market share volume is 250.000, and the stock has decreased by -0.070, or -4.760%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.